Chinthalapally V Rao from the University of Oklahoma Health Sciences Center, Oklahoma City, OK, US, talks to us about the protective role of aspirin and other NSAIDs in colorectal cancer.
1. What is currently known about the protective role of aspirin and other NSAIDs in colorectal cancer? (0:08)
2. Could you tell us a little about your recent study investigating intermittent dosing regimens of naproxen and aspirin in colon adenoma? (0:30)
3. How often and for how long should naproxen and aspirin be taken to achieve a protective effect? (1:18)
4. What are the limitations of this approach? (1:41)
5. What future studies are planned? (2:15)
Speaker disclosures: Chinthalapally V Rao has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
NSAIDS = non-steroidal anti-inflammatory drugs
Share this Video
Related Videos In Gastrointestinal Cancers
Upper gastrointestinal cancer highlights – KEYNOTE-585, KEYNOTE-811, MATTERHORN and SANO: Ken Kato, ASCO 2023
Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023. To summarise the findings from these key studies and their impact on the treatment of upper gastrointestinal cancers we caught up with esophageal oncologist […]
Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer
The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use of trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer, the secondary endpoint of overall survival and the key […]
Michael K Gibson, ASCO 2023: Highlights in upper GI oncology
touchONCOLOGY spoke with editorial board member Michael K Gibson (Vanderbilt University, Nashville, TN, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023 in the field of upper GI oncology, including the phase 3 ATTRACTION-5 study and a randomized, phase II study assessing toripalimab for the treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!